Roche up in arms as NICE advises NHS not to use Perjeta
This article was originally published in Scrip
Executive Summary
NICE, the health technology assessment institute for England and Wales, is gearing up to advise the NHS that Roche's breast cancer drug Perjeta (pertuzumab) should not be routinely used as it is not value for money. The Swiss pharma company has responded with strong criticism of the Department of Health (DH), which has delayed a review of the company's proposed patient access scheme, accusing it of letting patients down and pointing to flaws in the UK's "creaking system."